- Products & Services
- Partners & Programs
- About Affymetrix
Home > About Affymetrix
President and Chief Executive Officer
Dr. Frank Witney brings more than 30 years of experience in leadership and innovation in life science research, products, and diagnostic and analytical instruments to Affymetrix. He previously served at Affymetrix as Executive Vice President and Chief Commercial Officer following Affymetrix' acquisition of Panomics Inc., a quantitative biology company he pioneered for six years as President and Chief Executive Officer. Prior to his return to Affymetrix, Dr. Witney was President and Chief Executive Officer of Dionex Corp., leading this ion and high performance liquid chromatography company to a hugely successful acquisition by Thermo Fisher Scientific, Inc.
Dr. Witney also served as President and Chief Operating Officer of Packard BioScience, overseeing global operations, research and development, manufacturing, and worldwide sales, achieving rapid growth in revenues and operating profits. When Packard was acquired by PerkinElmer Life Sciences, he became President of PerkinElmer's Drug Discover Tools division, managing the reagent and instrument business units for high-throughput screening, research products, genomics/proteomics and liquid handling automation.
Earlier in his management career, Dr. Witney held a series of positions at Bio-Rad Laboratories, most recently as Group Operations Manager of the Life Science Group, leading efforts to enter rapidly growing markets for proteomic and bioassay technologies.
Dr. Witney was a post-doctoral fellow at the National Institutes of Health and holds a doctorate in molecular and cell biology from Indiana University.
Executive Vice President and Chief Financial Officer
Mr. Wood became our Executive Vice President and Chief Financial Officer in 2013. Mr. Wood joined Affymetrix in 2006 and has held a number of financial roles, including Vice President, Finance, International Controller, responsible for Europe and Asia Pacific. Prior to joining Affymetrix, Mr. Wood held a number of positions at the Unipart Group of Companies, including Business Unit Controller and Business Process Manager for implementing major enterprise resource planning systems in North America. Mr. Wood is a Chartered Accountant who qualified with the London Accountancy Practice Morgan Brown Spofforth in 1997 before continuing his career with Grant Thornton LLP.
Executive Vice President and Chief Commercial Officer
Mr. Weber brings over 30 years of experience in the life science industry. In his role as Executive Vice President and Chief Commercial Officer, he oversees Global Sales, Customer Service and Support, Sales and Service Operations, and Marketing Communications. Mr. Weber previously served as President of MomentusBio, a life sciences consulting company, and prior to that as Vice President of the Life Science Practice for The Linus Group, a life sciences marketing firm. Earlier in his career, Mr. Weber was President and CEO of Eksigent Technologies; Senior Vice President of Marketing and Business Development for Stratagene; and President, Americas Region, for Amersham Biosciences (GE Healthcare). Mr. Weber is a Henry Rutgers Scholar with a B.S. in Biochemistry from Rutgers University and is a member of the Phi Beta Kappa Honor Society. He has also served on the Board of the Analytical Life Science and Diagnostics Association (ALDA), formerly known as the Analytical and Life Science Systems Association (ALSSA).
Executive Vice President and Chief Operating Officer
Dr. Last has 25 years of global experience in the life science, pharmaceutical, diagnostics, and agrochemical industries. In his role as Executive Vice President and Chief Operating Officer, he oversees all our Business Units, Global Operations, QA/QC, and Regulatory Functions. Dr. Last previously served as Vice President, Global Marketing and Strategic Planning at BD Biosciences Cell Analysis and General Manager of the company's Pharmingen Business. He has also held senior management positions at Applied Biosystems and Incyte Genomics. Dr. Last holds a Ph.D. in Agrochemical Specialization and a Master's degree in Bio-Aeronautics from Cranfield University in the UK and a Bachelor's degree in Biological Sciences from the University of Leicester, UK.
Senior Vice President, General Counsel and Secretary
Ms. Chin brings a broad range of legal experience to Affymetrix, having spent, collectively, approximately 20 years in private legal practice and public company management. Ms. Chin joined Affymetrix in 2007. Prior to joining Affymetrix, Ms. Chin practiced law at Shearman & Sterling and Slaughter and May. Ms. Chin received her law degree from the King's College, University of London.
Senior Vice President and General Manager, Genetic Analysis Business Unit
Dr. Bellon brings more than 20 years of experience in general management, business development, research and development, and operations in the life science and molecular diagnostics industries. In his role as Senior Vice President and General Manager of the Genetic Analysis Business Unit, he is responsible for Affymetrix' Clinical and Genotyping Strategic Marketing, Research and Development, and Global Operations. Dr. Bellon previously served at Affymetrix as Vice President of Genetic Analysis Research and Development, Program Management, Business Development, and Operations. Prior to joining Affymetrix in 2006, he held senior management positions at Applied Biosystems, Life Technologies, and Ribozyme Pharmaceuticals. Dr. Bellon holds a Ph.D. in Bio-Organic Chemistry and a Master's degree in Biochemistry, both from University Sciences et Techniques, Montpellier, France.
Senior Vice President, Expression Business Unit
Dr. St. Louis has 25 years of global experience in the life science and diagnostic industries. In his role as Senior Vice President of the Expression Business Unit, he is responsible for all Research and Development, Marketing, and Customer Service initiatives. Dr. St. Louis served as Vice President of Global Research and Development at eBioscience and joined Affymetrix through our acquisition of the company in 2012. He also held senior management positions at Invitrogen and BD Biosciences. Dr. St. Louis holds a Ph.D. in Biochemistry from the University of British Columbia and a B.S. in Biochemistry from McGill University.
Senior Vice President, eBioscience Business Unit
Mr. Ward has over 25 years of global experience developing and commercializing products in the life science research products and diagnostic sectors. In his role as Senior Vice President and General Manager of the eBioscience Business Unit, he is responsible for the cell and protein analysis portfolio at Affymetrix. Mr. Ward served as Vice President of Commercial Operations at eBioscience from 2007 through the acquisition of the company by Affymetrix in 2012. Previously, he held positions of increasing responsibility at BD Biosciences in Research and Development, and he has over 18 years of experience in the marketing of research and diagnostic reagents and systems. Mr. Ward holds an MBA from Santa Clara University and a B.S. in Microbiology from Cal Poly San Luis Obispo.
Vice President, Life Science Reagents Business Unit
Mr. Magro has 15 years of experience in the healthcare and life science industries where he has served in leadership roles across sales, marketing, commercial operations, quality, and training and development. Prior to joining Affymetrix in 2008, Mr. Magro led Sales Operations for the Patient Monitoring business at GE Healthcare. During his 11 years with GE, Mr. Magro held a variety of management roles in sales, driving consistent revenue growth with a focus on customer satisfaction. He earned certification as a Six Sigma Black Belt while improving commercial effectiveness, training Green Belts, and mentoring process improvement projects across the commercial team. Mr. Magro earned his MBA from the Kelley School of Business at Indiana University and holds a BSE in Industrial and Operations Engineering from the University of Michigan.
Senior Vice President, Human Resources
Ms. Ting joined Affymetrix in 2014 to lead the global Human Resources organization, bringing over 20 years of combined finance and HR expertise. Prior to joining Affymetrix, Ms. Ting served as Vice President of Human Resources and Compensation at Varian Medical Systems where she was instrumental in the creation of the company's talent management strategy and led the transformation of its global HR systems and processes. Ms. Ting brings significant global compensation, talent strategy, and HR operations experience from her 14 years at Varian, having contributed toward the company's growth from 1,900 to 6,500 employees. Prior to Varian, Ms. Ting worked at PricewaterhouseCoopers LLP (formerly Coopers & Lybrand LLP) in Los Angeles. Ms. Ting holds a Bachelor's degree in Communications Studies with an emphasis in Business Administration from the University of California, Los Angeles.
Affymetrix Founder and Chairman
Stephen P.A. Fodor, Ph.D. is our Founder and Chairman. Dr. Fodor has served as director since 1993. He served as Chief Executive Officer from 1997 to 2008 and as Chairman from 1999 to present. At various times between 1993 and 1997, Dr. Fodor served as President, Chief Operating Officer and Chief Technology Officer. Dr. Fodor was Vice President and Director of Physical Sciences at the Affymax Research Institute from 1989 to 1993. Dr. Fodor is the founder and Chief Executive Officer of Cellular Research, Inc. and serves as a Trustee of the Carnegie Institution of Science and as a member of the National Academy of Engineering. Dr. Fodor also serves on a variety of scientific advisory boards. The Board of Directors selected Dr. Fodor as a director nominee because he is the founder of the Company and our former Chief Executive Officer. The Board of Directors values Dr. Fodors extensive knowledge of the Company and our industry, his scientific vision and his perspective on emerging technologies and markets.
Affymetrix President and Chief Executive Officer
Frank Witney, Ph.D. has served as President, Chief Executive Officer and a director since July 2011. Dr. Witney served as President and Chief Executive Officer of Dionex Corporation from April 2009 to May 2011. Between December 2008 and April 2009, Dr. Witney served as our Executive Vice President and Chief Commercial Officer. Previously, Dr. Witney served as President and Chief Executive Officer of Panomics, Inc. from July 2002 to December 2008. The Board of Directors selected Dr. Witney as a director nominee because the Board values Dr. Witneys industry experience and his perspective as the Chief Executive Officer of the Company.
Chief Executive Officer (Retired)
Magellan Navigation, Inc.
Nelson C. Chan has served as a director since March 2010 and is the Chairman of the Audit Committee and a member of the Compensation Committee. Mr. Chan served as Chief Executive Officer of Magellan Navigation, Inc. from 2006 to 2008. From 1992 through 2006, Mr. Chan served in various senior management positions with SanDisk Corporation, including most recently as Executive Vice President and General Manager, Consumer Business. Mr. Chan is a member of the Board of Directors of Coinstar, Inc. and Synaptics Incorporated. The Board of Directors selected Mr. Chan as a director nominee because of his substantial experience with public and private companies, both as an executive and as a board member, and his expertise in building profitable technology companies. Mr. Chan also qualifies as a financial expert and serves as Chairman of the Audit Committee.
President and Chief Executive Officer
Gary S. Guthart, Ph.D. has served as a director since May 2009 and is a member of the Compensation Committee. Dr. Guthart has served as the Chief Executive Officer of Intuitive Surgical, Inc. since January 2010. Dr. Guthart joined Intuitive Surgical, Inc. in April 1996, became Chief Operating Officer in 2006, and was promoted to President in 2007. Prior to joining Intuitive Surgical, Inc., Dr. Guthart was part of the core team developing foundation technology for computer enhanced-surgery at SRI International (formally Stanford Research Institute). Dr. Guthart serves on the Board of Directors of Intuitive Surgical, Inc. The Board of Directors selected Dr. Guthart as a director nominee because of his experience in the management of complex, high-growth businesses. The Board values Dr. Gutharts contribution to the Companys strategic planning and business development efforts and his insights as a member of the Compensation Committee.
Corporate Vice President of the Sales and Marketing Group and Director of Worldwide Marketing (Retired)
Jami Dover Nachtsheim has served as a director since March 2010 and is the Chairwoman of the Compensation Committee. Ms. Nachtsheim served in a variety of positions with Intel Corporation from 1980 until her retirement in 2000, most recently as Corporate Vice President of the Sales and Marketing Group and Director of Worldwide Marketing. Ms. Nachtsheim is a member of the Board of Directors of FEI Company and The Tech Museum of Innovation. The Board of Directors selected Ms. Nachtsheim as a director nominee because of her extensive experience in bringing high technology products to market and her service as a board member of numerous public and private organizations. The Board values the guidance she provides with respect to market strategies and her contributions as the Chairwoman of the Compensation Committee.
Senior Vice President, Strategy and Business Development (Retired)
Lockheed Martin Corporation
Robert H. Trice, Ph.D. has served as a director since 2006, is the Chairman of the Nominating and Corporate Governance Committee and a member of the Audit Committee. Dr. Trice served as Senior Vice President for Business Development at Lockheed Martin Corporation from October 1998, and assumed additional duties as Senior Vice President for Strategy and Business Development at Lockheed Martin Corporation from March 2009 until his retirement in January 2011. The Board of Directors selected Dr. Trice as a director nominee because of his broad experience in government relationships (many of our large customers are government institutions) and his extensive background as a business development leader. The Board values his financial literacy and wide-ranging business competencies, which qualify him to serve on the Audit Committee and the Nominating and Corporate Governance Committee.
Executive Vice President and Chief Financial Officer (Retired)
Robert P. Wayman has served as a director since 2007, is our lead independent director and a member of the Audit Committee and the Nominating and Corporate Governance Committee. Mr. Wayman served as Executive Vice President and Chief Financial Officer of Hewlett-Packard Company from 1984 until his retirement in December 2006. Mr. Wayman also served as Interim Chief Executive Officer of Hewlett-Packard Company from February 2005 through March 2005 and served on the Board of Directors of Hewlett-Packard Company from February 2005 to March 2007 and from 1993 to 2002. Mr. Wayman has served as a director of CareFusion Corp. since 2009. The Board of Directors selected Mr. Wayman as a director nominee because of his broad-based financial expertise and business experience. The Board of Directors values Mr. Waymans background in finance and company operations, corporate governance and compliance, and the leadership that he has provided as the lead independent director and as a member of the Audit Committee and the Nominating and Corporate Governance Committee.
アフィメトリクスのGeneChip®テクノロジーは、1980年代後半にStephen P.A. Fodor博士率いる科学者チームによって発明されました。これは半導体の製造技術をコンビナトリアルケミストリーと組み合わせ、微小なガラスチップの上に多量の生物学的データを構築するという革新的な理論に基づいた技術です。この技術をもとにして1991年、Affymax, N.V.の1部門が設立されましたが翌年1992年、新会社アフィメトリクスとして独立・創業しました。カリフォルニア州サンタクララに本社をおき、1996年6月には新規に株式公開いたしました。
2012年6月 株式非公開企業eBioscience Holding Company, Inc.（本社カリフォルニア州サンディエゴ）を買収しました。eBioscienceは免疫学やオンコロジー領域のフローサイトメトリーとイムノアッセイ用試薬のリーディングカンパニーで、ライフサイエンスの研究および診断向けに非常に多数の抗体やELISAおよびタンパク質の品揃えを有しています。
True Materials Inc.
2008年7月、株式非公開企業True Materials Inc.（本社サンフランシスコ）を買収しました。この会社は、1万ものマーカーを同時分析できる技術を開発していました。
2007年12月、株式非公開企業USB Corporation（本社オハイオ州クレーブランド）を買収しました。これにより、分子生物学および生化学試薬の幅広い製品ラインを提供可能になりました。100％子会社のAnatrace Inc.（膜タンパク質の抽出・精製用製品を製造）も買収対象となりました。
ParAllele BioScience Inc.
Genetic MicroSystems, Inc.